GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (NAS:VNDA) » Definitions » EV-to-Revenue

Vanda Pharmaceuticals (Vanda Pharmaceuticals) EV-to-Revenue : -0.54 (As of May. 01, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Vanda Pharmaceuticals's enterprise value is $-104.7 Mil. Vanda Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $192.6 Mil. Therefore, Vanda Pharmaceuticals's EV-to-Revenue for today is -0.54.

The historical rank and industry rank for Vanda Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

VNDA' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.34   Med: 2.8   Max: 14.55
Current: -0.54

During the past 13 years, the highest EV-to-Revenue of Vanda Pharmaceuticals was 14.55. The lowest was -1.34. And the median was 2.80.

VNDA's EV-to-Revenue is ranked better than
93.4% of 1031 companies
in the Biotechnology industry
Industry Median: 7.91 vs VNDA: -0.54

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-01), Vanda Pharmaceuticals's stock price is $4.865. Vanda Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $3.35. Therefore, Vanda Pharmaceuticals's PS Ratio for today is 1.45.


Vanda Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Vanda Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vanda Pharmaceuticals EV-to-Revenue Chart

Vanda Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.56 1.48 1.70 -0.14 -0.71

Vanda Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.14 -0.39 -0.42 -1.09 -0.71

Competitive Comparison of Vanda Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Vanda Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's EV-to-Revenue falls into.



Vanda Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Vanda Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-104.694/192.64
=-0.54

Vanda Pharmaceuticals's current Enterprise Value is $-104.7 Mil.
Vanda Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $192.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vanda Pharmaceuticals  (NAS:VNDA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Vanda Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=4.865/3.348
=1.45

Vanda Pharmaceuticals's share price for today is $4.865.
Vanda Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.35.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vanda Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals (Vanda Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.
Executives
Joakim Wijkstrom officer: SVP, Chief Marketing Officer 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC DC 20037
Stephen Ray Mitchell director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVE., SUITE 300E, WASHINGTON DC 20037
Kevin Patrick Moran officer: VP, Acting CFO & Treasurer C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Timothy Williams officer: SVP & General Counsel C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON DC 20037
Tage Honore director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Mihael Hristos Polymeropoulos director, officer: Chief Executive Officer 9605 MEDICAL CENTER DRIVE SUITE 300, ROCKVILLE MD 20850
Gunther Birznieks officer: SVP, Business Development 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Thomas Watkins director 1221 GULF SHORE BLVD N #303, NAPLES FL 34102
Aranthan Ii Jones officer: Chief Corp. Affairs Officer 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC DC 20037
Phaedra Chrousos director 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Richard W Dugan director 20425 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
James Patrick Kelly officer: SVP, CFO, Treasurer & Secretar C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gian Piero Reverberi officer: SVP, General Manager Europe 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Anne Sempowski Ward director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341